Silexion Therapeutics Files 8-K
Ticker: SLXNW · Form: 8-K · Filed: Aug 20, 2025 · CIK: 2022416
Sentiment: neutral
Topics: 8-K, corporate-update, financials
TL;DR
Silexion Therapeutics (fka Biomotion) filed an 8-K on 8/20/25. Routine update.
AI Summary
Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on August 20, 2025, reporting other events and financial statements. The company, incorporated in the Cayman Islands, is based in Ramat Gan, Israel, and operates in the biological products sector. This filing serves as a routine update on corporate events and financial disclosures.
Why It Matters
This 8-K filing indicates routine corporate updates and financial disclosures from Silexion Therapeutics Corp., formerly known as Biomotion Sciences.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for other events and financial statements, with no immediate indication of significant risk or material change.
Key Numbers
- 001-42253 — Commission File Number (Identifies the company's SEC filings)
- 20250820 — Filing Date (Date the 8-K was filed)
Key Players & Entities
- Silexion Therapeutics Corp (company) — Registrant
- Biomotion Sciences (company) — Former company name
- August 20, 2025 (date) — Date of report
- 001-42253 (other) — Commission File Number
- 12 Abba Hillel Road Ramat-Gan , Israel (address) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing is for reporting 'Other Events' and 'Financial Statements and Exhibits' as of August 20, 2025.
What was Silexion Therapeutics Corp.'s former name?
Silexion Therapeutics Corp.'s former name was Biomotion Sciences, with a date of name change on May 6, 2024.
Where are Silexion Therapeutics Corp.'s principal executive offices located?
The principal executive offices are located at 12 Abba Hillel Road, Ramat-Gan, Israel, 5250606.
What is the company's Standard Industrial Classification (SIC) code?
The company's SIC code is 2836, categorized under 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)'.
What is the company's Commission File Number?
The company's Commission File Number is 001-42253.
Filing Stats: 689 words · 3 min read · ~2 pages · Grade level 11.3 · Accepted 2025-08-20 16:53:33
Key Financial Figures
- $0.0135 — registered Ordinary Shares, par value $0.0135 per share SLXN The Nasdaq Stock Mar
- $1,552.50 — Ordinary Shares at an exercise price of $1,552.50 per share SLXNW The Nasdaq Stock Ma
Filing Documents
- zk2533676.htm (8-K) — 45KB
- exhibit_99-1.htm (EX-99.1) — 1421KB
- image00006.jpg (GRAPHIC) — 16KB
- 0001178913-25-003005.txt ( ) — 9701KB
- slxn-20241231.xsd (EX-101.SCH) — 149KB
- slxn-20241231_cal.xml (EX-101.CAL) — 43KB
- slxn-20241231_def.xml (EX-101.DEF) — 371KB
- slxn-20241231_lab.xml (EX-101.LAB) — 1409KB
- slxn-20241231_pre.xml (EX-101.PRE) — 483KB
- zk2533676_htm.xml (XML) — 1518KB
01
Item 8.01 Other Events. As previously reported, on July 28, 2025, the board of directors of Silexion Therapeutics Corp (the " Company ") effected a 1-for-15 reverse share split of all of the Company's issued and outstanding, and authorized but unissued, ordinary shares (the " Reverse Share Split "). The Reverse Share Split had been approved by the Company's shareholders pursuant to Proposal 3 presented at the 2025 annual general meeting of the Company, which was initially held on July 7, 2025 and reconvened on July 14, 2025. The Company's ordinary shares began trading on a post-Reverse Share Split-adjusted basis on the Nasdaq Capital Market at the open of the market on July 29, 2025. Following the Reverse Share Split, the Company has retroactively adjusted the share, per share and related option and warrant information included in the Company's audited financial statements for the year ended December 31, 2024 (which financial statements reflect the results of Silexion Therapeutics Ltd., the Company's wholly-owned subsidiary and the Company's predecessor company from an accounting perspective, from January 1, 2024 through August 15, 2024) (the " 2024 Financials ") to reflect the reduced number of ordinary shares and the increased share price which resulted from the Reverse Share Split. The updated 2024 Financials, reflecting the Reverse Share Split, are attached hereto as Exhibit 99.1, and are incorporated by reference into this Item 8.01.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits 99.1 Updated audited financial statements of Silexion Therapeutics Corp as of, and for the year ended on, December 31, 2024 101.INS* Inline XBRL Instance Document. 101.SCH* Inline XBRL Taxonomy Extension Schema Document. 101.CAL* Inline XBRL Taxonomy Extension Calculation Linkbase Document. 101.DEF* Inline XBRL Taxonomy Extension Definition Linkbase Document. 101.LAB* Inline XBRL Taxonomy Extension Label Linkbase Document. 101.PRE* Inline XBRL Taxonomy Extension Presentation Linkbase Document. 104* Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SILEXION THERAPEUTICS CORP Date: August 20, 2025 By: /s/ Ilan Hadar Name: Ilan Hadar Title: Chief Executive Officer